Meeting
2022 ASCO Annual Meeting
Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study.
Authors
Peter A. Fasching
University Hospital Erlangen, Comprehensive Cancer Center (CCC) Erlangen-EMN, Friedrich-Alexander University Erlangen-Nürnberg, Erlangen, Germany
Peter A. Fasching , Aditya Bardia , Vanesa Quiroga , Yeon Hee Park , Isabel Blancas , Jose Luis Alonso , Alexander Vasilyev , Hryhoriy Adamchuk , Marcelo Ramos Tejo Salgado , Denise A. Yardley , Gonzalo Spera , Cloris Xue , Erika Ferreira , Tanja Badovinac Crnjevic , Pablo Diego Pérez-Moreno , Vanesa López-Valverde , Jutta Steinseifer , Tharu M. Fernando , Heather M. Moore , Sara A. Hurvitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT04436744
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 589)
DOI
10.1200/JCO.2022.40.16_suppl.589
Abstract #
589
Poster Bd #
360
Abstract Disclosures
Similar Posters
First Author: Yeon Hee Park
Poster
2020 ASCO Virtual Scientific Program
A phase II trial of nivolumab (NIVO) + palbociclib (PAL) + anastrozole (ANA) in postmenopausal women and men with estrogen receptor (ER)+/human epidermal growth factor 2 (HER2)- primary breast cancer (BC): CheckMate 7A8.
First Author: Sara M. Tolaney
Poster
2020 ASCO Virtual Scientific Program
A phase Ib study to evaluate the oral selective estrogen receptor degrader GDC-9545 alone or combined with palbociclib in metastatic ER-positive HER2-negative breast cancer.
First Author: Elgene Lim
Poster
2017 ASCO Annual Meeting
Phase II trial of neoadjuvant (neo) palbociclib (Palbo) plus anastrozole (ana) in endocrine resistant clinical stage 2/3 estrogen receptor positive and HER2 negative (ER+ HER2-) breast cancer (BC).
First Author: Nusayba Ali Bagegni